We previously analyzed our tissue NGS datasets and publicly available mPC datasets, concluding that BRCA1/2-mutated metastatic tumors differ from wild-type tumors in PSA levels at diagnosis. The gene discussed is BRCA1; the disease is metastatic neoplasm.